Dr. Reddy's Labs Receives FDA Form 483

Published 1 year ago

Dr. Reddy's Laboratories' Miryalaguda API facility in India underwent a US FDA GMP inspection (May 19-24, 2025), resulting in a Form 483 with two observations. The company plans to address them promptly.

FDA inspected Dr. Reddy’s Miryalaguda facility.
Form 483 issued with 2 observations.
The company will address observations quickly.

You might like these

Sterling Gtake EV Chargers Launch India

Tata Power Wins Kerala BESS Project

RBI Issues New AIF Investment Rules

SEBI Penalizes BSE 2.5 Million Rupees for Compliance Failures

Reliance to Boost India's Solar Capacity

Oil Prices Fall on OPEC+ Supply Increase Talk

India, Israel Ink Investment Pact